莫西沙星仿制药与原研药临床治疗的药物经济学评价

Pharmacoec onomic Evaluati on of Generic and Brand-name Moxifloxacin in Clinical Treatment

目的通过药物经济学评价对比莫西沙星仿制药之间、仿制药与原研药之间临床治疗有效性和经济性。方法应用回顾性研究方法,收集医院2019年全年住院使用莫西沙星注射液符合条件的患者1692例,不良反应31例,根据药物生产厂家不同将患者分为A、B、C三组,以有效率、不良反应发生率作为指标,通过最小成本分析法、成本-效果(C/E)、增量成本-效果比(△C/△E),分析3种治疗方案的药物经济学评价,并通过药费下调30%进行敏感度分析。结果A、B、C三组成本分别为1786.15元、1560.59元、1241.65元,临床有效率分别为92.0%、91.0%、90.4%,不良反应发生率分别为2.65%、2.09%和1.22%,无显著性差异(P>0.05),C/E分别为19.41、17.15、13.74,A组对C组、B组对C组的△C/△E分别为340.31、531.57。敏感性分析支持成本-效果分析的结果。结论莫西沙星仿制药与原研药在有效性和安全性方面无显著性差异,根据最小成本分析C组莫西沙星仿制药更具经济学优势。

OBJECTIVE The pharmacoeconomic evaluation was used to compare the clinical efficacy and cost effectiveness between moxifloxacin s generic drugs and the brand-name drug.METHODS A retrospective study was carried out,in which there were totally 1,692 eligible cases using moxifloxacin injections in our hospital in2019.According to different drug manufacturers,patients were divided into three groups:Group A,Group B andGroup C.The clinical efficacy and the adverse drug reactions were compared among the three groups.The pharmaco-economic evaluation of the three groups were analyzed by means of minimum cost analysis,cost-effectiveness and in-cremental cost-effectiveness ratio.The sensitivity analysis was performed by reducing the drug cost by 30%.RESULTS The costs of the three groups were 1,786.15 Yuan,1,560.59 yuan and 1,241.65 Yuan respective-ly.The clinical effective ratios of the three groups were 92.0%,91.0%,and 90.4% respectively and the incidencesof adverse drug reactions were 2.65%,2.09% and 1.22% respectively with no significant difference in the threegroups(P>0.05).Cost-effectiveness ratios of the three groups were 19.41,17.15 and 13.74 respectively.The in-cremental cost-effectiveness ratio for Group A to Group C was 340.31 and the one for Group B to Group C was531.57.The results of cost-effectiveness analysis were supported by sensitivity analysis.CONCLUSION There isno significant dfference in clinical effectiveness and safety between generic and brand-name of moxifloxacin,On acost-minimization basis,moxifloxacin generic drugs in Group C have an economic advantage.